NBRV - Merck Nabriva terminate distribution agreement for antibacterial

• Nabriva Therapeutics ( NASDAQ: NBRV ) and Merck ( NYSE: MRK ) have decided to part ways in the U.S. distribution of Sivextro, an antibacterial indicated for skin and skin structure infections (ABSSSI) caused by certain Gram-positive microorganisms.
• In July 2020, the two companies entered into an agreement under which Nabriva ( NBRV ) exclusively licensed the right to promote, distribute and commercialize the treatment in the U.S.
• In a regulatory filing, Nabriva ( NBRV ) stated that on Jan. 31, the parties amended the deal, converting the company's exclusive license to promote, distribute and commercialize Sivextro into a non-exclusive license and terminating the distribution pact effective June 30.
• "After June 30, 2023, the Company will no longer have the right to promote, distribute or commercialize SIVEXTRO," Nabriva ( NBRV ) said, adding that until then, it will continue to offer the treatment for wholesale customers and recognize the revenue.
• Sivextro added $24.2M in product revenue for the company during the first nine months of 2022, making up ~92% of its topline.

For further details see: